Preferred Label : Mozistobart Zoratolimod;
NCIt synonyms : Anti-CD22-T-CpG Conjugate TAC-001; TLR9 Agonist/Anti-CD22 Antibody Conjugate TAC-001; TRAAC TAC-001; Toll-like Receptor Agonist Antibody Conjugate TAC-001;
NCIt definition : A toll-like receptor (TLR) agonist antibody conjugate (TRAAC) composed of mozistobart,
a humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody that is directed against
the B-cell restricted antigen CD22, conjugated at one glutamine residue with zoratolimod,
an unmethylated oligonucleotide-based TLR 9 agonist (T-CpG), with potential immunostimulating
and antineoplastic activities. Upon intravenous administration of mozistobart zoratolimod,
the mozistobart moiety targets and binds to CD22 on B-cells, including tumor-infiltrating
B-cells, thereby systemically delivering zoratolimod to B-cells. In turn, the zoratolimod
moiety binds to the TLR9 receptor expressed on tumor-infiltrating B-cells in the tumor
microenvironment (TME), which activates B-cells and induces TLR-mediated signaling.
This activates innate and adaptive immune responses and leads to a cytotoxic T-lymphocyte
(CTL)-mediated anti-tumor immune response. TLR9, a member of the TLR family, plays
a fundamental role in pathogen recognition and activation of the innate immune system.
CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant
B-cells.;
UNII : 4WQE3D6M5H;
CAS number : 2852752-99-7;
Molecule name : TAC-001; TAC 001;
NCI Metathesaurus CUI : CL1799129;
Origin ID : C190597;
UMLS CUI : C5787236;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
